autologous induced pluripotent stem cells transduced with alpha-1 antitrypsin (DNAVEC/University of Cambridge/Wellcome Trust/Sangamo/Institut Pasteur/INSERM/University of Rome)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameautologous induced pluripotent stem cells transduced with alpha-1 antitrypsin (DNAVEC/University of Cambridge/Wellcome Trust/Sangamo/Institut Pasteur/INSERM/University of Rome)
Drug Alias NameA1AT-expressing pluripotent stem cells (DNAVEC/University of Cambridge/Wellcome Trust/Sangamo/Institut Pasteur/INSERM/University of Rome)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionAlpha-1-antiproteinase stimulants
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesID Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversita degli Studi di Roma La SapienzaID Pharma Co LtdInserm +[7] 
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A